A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2023 Nov 24

PMID 37997979

Authors

Blerida Banushi

Vince Polito

Affiliations

Soon will be listed here.

Abstract

Psychedelic substances have gained significant attention in recent years for their potential therapeutic effects on various psychiatric disorders. This review delves into the intricate cellular neurobiology of psychedelics, emphasizing their potential therapeutic applications in addressing the global burden of mental illness. It focuses on contemporary research into the pharmacological and molecular mechanisms underlying these substances, particularly the role of 5-HT2A receptor signaling and the promotion of plasticity through the TrkB-BDNF pathway. The review also discusses how psychedelics affect various receptors and pathways and explores their potential as anti-inflammatory agents. Overall, this research represents a significant development in biomedical sciences with the potential to transform mental health treatments.

Citing Articles

Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology.

Brengel E, Axe B, Maheswari A, Abeer M, Ortiz R, Woodward T bioRxiv. 2025; .

PMID: 39975204 PMC: 11838531. DOI: 10.1101/2025.02.03.636248.

Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome.

Balaji S, Woodward T, Richter E, Chang A, Otiz R, Kulkarni P Front Neurosci. 2024; 18:1506352.

PMID: 39664446 PMC: 11631868. DOI: 10.3389/fnins.2024.1506352.

Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options.

Larrea A, Sanchez-Sanchez L, Diez-Martin E, Elexpe A, Torrecilla M, Astigarraga E J Clin Med. 2024; 13(6).

PMID: 38541952 PMC: 10971738. DOI: 10.3390/jcm13061727.

References

Jones K, Srivastava D, Allen J, Strachan R, Roth B, Penzes P . Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A. 2009; 106(46):19575-80. PMC: 2780750. DOI: 10.1073/pnas.0905884106. View

Carbonaro T, Bradstreet M, Barrett F, MacLean K, Jesse R, Johnson M . Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12):1268-1278. PMC: 5551678. DOI: 10.1177/0269881116662634. View

Banks M, Zahid Z, Jones N, Sultan Z, Wenthur C . Catalysts for change: the cellular neurobiology of psychedelics. Mol Biol Cell. 2021; 32(12):1135-1144. PMC: 8351556. DOI: 10.1091/mbc.E20-05-0340. View

Nutt D, Erritzoe D, Carhart-Harris R . Psychedelic Psychiatry's Brave New World. Cell. 2020; 181(1):24-28. DOI: 10.1016/j.cell.2020.03.020. View

Phoumthipphavong V, Barthas F, Hassett S, Kwan A . Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex. eNeuro. 2016; 3(2). PMC: 4819286. DOI: 10.1523/ENEURO.0133-15.2016. View

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R . Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021; 384(15):1402-1411. DOI: 10.1056/NEJMoa2032994. View

Jakab R, Goldman-Rakic P . 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95(2):735-40. PMC: 18490. DOI: 10.1073/pnas.95.2.735. View

Davis A, Barrett F, May D, Cosimano M, Sepeda N, Johnson M . Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020; 78(5):481-489. PMC: 7643046. DOI: 10.1001/jamapsychiatry.2020.3285. View

Rueda C, Llorente-Folch I, Traba J, Amigo I, Gonzalez-Sanchez P, Contreras L . Glutamate excitotoxicity and Ca2+-regulation of respiration: Role of the Ca2+ activated mitochondrial transporters (CaMCs). Biochim Biophys Acta. 2016; 1857(8):1158-1166. DOI: 10.1016/j.bbabio.2016.04.003. View

10.

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, Richards B . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-1197. PMC: 5367557. DOI: 10.1177/0269881116675513. View

11.

Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B . The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. J Psychoactive Drugs. 2022; 55(1):1-10. DOI: 10.1080/02791072.2021.2022254. View

12.

Olson D . Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018; 12:1179069518800508. PMC: 6149016. DOI: 10.1177/1179069518800508. View

13.

Johnson M, Richards W, Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22(6):603-20. PMC: 3056407. DOI: 10.1177/0269881108093587. View

14.

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

15.

Bourrie B, Bouaboula M, Benoit J, Derocq J, Esclangon M, Le Fur G . Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Eur J Immunol. 1995; 25(10):2882-7. DOI: 10.1002/eji.1830251026. View

16.

Kenakin T . Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol. 2011; 165(6):1659-1669. PMC: 3372820. DOI: 10.1111/j.1476-5381.2011.01749.x. View

17.

Cohen S . Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. 1960; 130:30-40. DOI: 10.1097/00005053-196001000-00005. View

18.

McNamee S, Devenot N, Buisson M . Studying Harms Is Key to Improving Psychedelic-Assisted Therapy-Participants Call for Changes to Research Landscape. JAMA Psychiatry. 2023; 80(5):411-412. DOI: 10.1001/jamapsychiatry.2023.0099. View

19.

Aydemir O, Deveci A, Taneli F . The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2):261-5. DOI: 10.1016/j.pnpbp.2004.11.009. View

20.

Nichols D . Psychedelics. Pharmacol Rev. 2016; 68(2):264-355. PMC: 4813425. DOI: 10.1124/pr.115.011478. View